Millipore and JPT Announces Distribution Agreement
Complete the form below to unlock access to ALL audio articles.
Millipore Corporation and JPT Peptide Technologies GmbH, a wholly-owned subsidiary of Berlin-based Jerini AG have announced a distribution and marketing agreement.
This relationship gives Millipore worldwide, non-exclusive distribution rights for JPT’s line of enzyme profiling products and services targeting enzymes such as kinases, phosphatases and proteases.
This includes JPT’s line of Enzyme Substrate Sets and Microarrays containing thousands of peptides with annotated phosphorylation/cleavage sites to study enzymatic activities and substrate specificities.
"JPT’s unique peptide-based products strongly complement our existing portfolio of cell signaling reagents and services," states Rick Ryan, vice president of the Drug Discovery business unit for the Bioscience Division of Millipore Corporation.
"This will give Millipore customers access to patented high-throughput peptide synthesis and screening platforms, which accelerates research in the field of signal transduction."
"We applied our peptide synthesis and peptide array technologies to develop a series of tailor-made products and services to address the increasing demand in the field of kinase and protease research," comments Holger Wenschuh, managing director at JPT.
"We look forward to expanding the availability of these tools through Millipore’s worldwide, dedicated sales channels."
